Hydrocortisone Compared with Placebo in Patients with Septic Shock Satisfying the Sepsis-3 Diagnostic Criteria and APROCCHSS Study Inclusion Criteria: A Post Hoc Analysis of the ADRENAL Trial.

2019-12

Venkatesh, Balasubramanian

Finfer, Simon

Cohen, Jeremy

Rajbhandari, Dorrilyn

Arabi, Yaseen

Bellomo, Rinaldo

Billot, Laurent

Glass, Parisa

Joyce, Christopher

Li, Qiang

McArthur, Colin

Perner, Anders

Rhodes, Andrew

Thompson, Kelly

Webb, Steve

Myburgh, John

Journal Article

0000-0002-1650-8939

10.1097/ALN.0000000000002955

Definitions and management strategies for septic shock continue to be updated as defined in Sepsis-2, Sepsis-3, and other guidelinesRecent randomized controlled trials of corticosteroids in septic shock report different treatment effects on 90-day mortality but use different inclusion criteria WHAT THIS ARTICLE TELLS US THAT IS NEW: In a post hoc analysis of the Adjunctive Glucocorticoid Therapy in Patients with Septic Shock (ADRENAL) trial, in participants who fulfilled either the Sepsis-3 or -2 inclusion criteria or those with severe septic shock, a continuous infusion of hydrocortisone did not result in a lower 90-day mortality than placebo BACKGROUND

link

Anesthesiology 2019; 13(6): 1292-1300

Anesthesiology